Oral contraceptives and heavy periods

Obstetrics and Gynecology

Volumn 117, Issue 4, 2011, Pages 773-774

  Drife, James O ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; ESTRADIOL VALERATE; ORAL CONTRACEPTIVE AGENT;

CANCER RISK; EDITORIAL; HORMONE SUBSTITUTION; HUMAN; MENSTRUATION; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERUS BLEEDING;

CONTRACEPTIVES, ORAL; ESTRADIOL; FEMALE; HUMANS; MENORRHAGIA; NANDROLONE;

EID: 79953211912     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318212b333     Document Type: Editorial

References (6)

1. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl E2 for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-20.
2. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. The Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD000154. DOI: 10.1002/ 14651858.CD000154.pub2.
3. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. National Center for Health Statistics. Vital Health Stat 23. 2010;29:1-44.
4. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,357 women with ovarian cancer and 78,303 controls. Lancet 2008;371:303-14.
5. Kaunitz AM. Hormonal contraception in women of older reproductive age. N Engl J Med 2008;358:1262-70. (Pubitemid 351439227)
6. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with E2 valerate and dienogest: a randomized study. Obstet Gynecol 2011;117:777-87.